Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (January 2025)
33 slides from Maat Pharma's investor presentation, January 2025
Slide 1: Boosting Survival Through Innovative Immune Modulation
Boosting Survival Through Innovative Immune Modulation January 2025
Slide 2: Disclaimer
MaaT Pharma January 2025 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward-looking statements. These and is for information and background purposes only. independent ve
Slide 3: Management Team
MaaT Pharma January 2025 3 Management Team Hervé Affagard Eric Soyer Gianfranco Pittari, Carole Sian Crouzet Jonathan Chriqui, MD, PhD Schwintner, PhD PharmD Co-Founder & CEO Chief Financial Chief Medical Chief Technology Chief of Staff Chief Business Officer Officer Officer Officer
Slide 4: Company Overview
Company Overview
Slide 5: MaaT013 in aGvHD: Primary Endpoint of Phase 3 Study Achieved
MaaT Pharma January 2025 5 MaaT013 in aGvHD: Primary Endpoint of Phase 3 Study Achieved Registration in Europe Spearheading Microbiome Therapies in Oncology Now available: Phase 3 Data in Multi-assets platform Funding aGvHD from the ARES study focused on oncology opportunities Primary endpoint: unpr
Slide 6: Correcting Dysbiosis: a New Pillar in Oncology
MaaT Pharma January 2025 6 Correcting Dysbiosis: a New Pillar in Oncology Dysbiosis and disease • Loss of microbial diversity • Increase in pathogens • Reduction of microbial metabolites • Associated with multiple conditions Microbiotherapy Restores Gut Microbiota Diversity and Production of Microbi
Slide 7: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma January 2025 7 Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Co-cultured Ecosystem In-house Production Driving near-term value Progressing next-generation Leading capabilities in full ecosystem with the donor-derived MET-N platform co-cultured scal
Slide 8: A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset
MaaT Pharma January 2025 8 A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset Program Indication Market potential Preclinical Phase 1 Phase 2 Phase 3 MAA Status Upcoming milestone Primary EU MAA Submission ARES MaaT013 1L : 10k patients2 endpoint met Mid 2025 2L
Slide 9: Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes
MaaT Pharma January 2025 9 Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings Control of inflammation and restoration of gut integrity and production of functional metabolites Resolution • Immune modulation Restoration of microbiota diversity
Slide 10: MaaT013 in aGvHD
MaaT013 in aGvHD
Slide 11: Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 11 Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD) → A significant complication following allogeneic hematopoietic stem cell transplantation (Allo-HSCT) → May occur in 50% of patients undergoing Allo-H
Slide 12: aGvHD Refractory to Steroids and ruxolitinib: A Substantial Unmet Medical Need
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 12 ODD EMA/FDA aGvHD Refractory to Steroids and ruxolitinib (3rd line of treatment): A Substantial Unmet Medical Need Requiring Innovative Solutions Treatment Paradigm Lack of effective therapy in 3rd line Corticosteroids
Slide 13: ARES: a Pivotal Phase 3 Trial Exploring MaaT013 in Third-Line aGvHD
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 13 ARES: a Pivotal Phase 3 Trial Exploring MaaT013 in Third-Line aGvHD Following Steroid and ruxolitinib Failure Milestones: Topline results announced January 8th 2025 I OS expected by end of 2025 I Regulatory submission e
Slide 14: ARES patients: Baseline Characteristics
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 14 ARES patients: Baseline Characteristics Patients characteristics at baseline All patients receiving MaaT013 (n=66) Median age, years (range) 55.5 (24; 76) Gender n (%) Male: 35 (53%) Female: 31 (47%) Steroid status n (%
Slide 15: ARES: Strong Response to MaaT013 in aGvHD following Steroid and ruxolitinib Failure
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 15 ARES: Strong Response to MaaT013 in aGvHD following Steroid and ruxolitinib Failure 80 95% CI (49%, 74%) 95% CI (51%, 75%) CR Topline Results D28 Response rate (%) 62% 64% PR VGPR VGPR 60 5% 9% PR CR 20% 20% 18% 18% • 6
Slide 16: ARES: Unprecedented Probability of Survival Compared to Historical Data with BAT
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 16 ARES: Unprecedented Probability of Survival Compared to Historical Data with Best Available Therapy (BAT) Overall Survival, ARES vs BAT Probability of Survival by D28 Response Probability of Survival (%) Probability of
Slide 17: Early Access Program: meeting critical needs in GvHD today and shaping the future
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 17 Early Access Program: meeting critical needs in GvHD today and shaping the future 1 2 3 4 Patients First Supplying The Increasing In Different Indications Clinical Value Number International Demand of patients 154 cumul
Slide 18: Clear Regulatory Path for MaaT013 in Third Line Refractory aGvHD
MaaT013 • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action January 2025 18 Clear Regulatory Path for MaaT013 in Third Line Refractory aGvHD In Europe In the U.S. Eligibility of MaaT013 for the centralized procedure Open IND: Ongoing dialogue with the FDA to expedite confirmed by EMA (Medicinal
Slide 19: A Multi-Asset Platform Focused on Oncology
A Multi-Asset Platform Focused on Oncology
Slide 20: Phoebus: MaaT033 Phase 2b RCT Adjunctive Treatment for Allo-HSCT Patients
→ Ambulatory MaaT033 • Allo-HSCT MaaT Pharma → Adjunctive January 2025 20 Phoebus: MaaT033 Phase 2b RCT Potential Adjunctive Treatment for Patients Receiving Allo-HSCT Visit 1 Visit 2 15 – 21 days Visit 3 Visit 6 Visit 10 D-21 D-7 D-0 Neutrophil recovery D+21 M+3 M+12 Pre Allo-HSCT Post Allo-HSCT tr
Slide 21: Unlocking the Potential of Checkpoint Inhibitors
→ ICI MaaT013 • IO - Melanoma MaaT Pharma → Combo January 2025 21 Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance Immune Checkpoint Inhibitors (ICI) significantly Leveraging full ecosystem microbiome improve outcomes in solid tumor pat
Slide 22: MaaT013 Evaluated in Phase 2 Randomized, Multicenter Clinical Trial in Melanoma
→ ICI MaaT013 • IO - Melanoma MaaT Pharma → Combo January 2025 22 MaaT013 Evaluated in Phase 2 Randomized, Multicenter Clinical Trial in Melanoma Phase 2a PICASSO trial, fully recruited Key study endpoints after 23 weeks of treatment: Investigator Sponsored Trial (Assistance Publique - Hôpitaux de P
Slide 23: MaaT033: Targeting Amyotrophic Lateral Sclerosis Progression
MaaT033 • ALS → Ambulatory MaaT Pharma January 2025 23 MaaT033: Targeting Amyotrophic Lateral Sclerosis Progression Amyotrophic Lateral Sclerosis (ALS) Rationale for Exploratory Utilization of MaaT033 in ALS → Could affect up to 60,000 patients in US & EU by 2040 1 → Microbiota-Gut-Brain axis is a m
Slide 24: MET-C Product Generation Driven by Proprietary Predictive AI
→ Synthetic MET-C • ICI and more → Tailored MaaT Pharma January 2025 24 MET-C Product Generation is Driven by MaaT Pharma’s Proprietary Predictive AI, Eubiotic Score and in vitro and in vivo Validation Processes MaaT034 MaaT034 In silico In vitro In vivo Clinic Candidate Products Upcoming Milestones
Slide 25: Hemato-oncology Franchise
Hemato- oncology Franchise Driving Value
Slide 26: MaaT013 Addressable Market and Revenues
→ Salvage MaaT013 • aGvHD → Quick action MaaT Pharma January 2025 26 MaaT013 Addressable Market and Revenues Addressable market in 3L Estimated Annual Revenues ~3,000 patients 65% Market penetration 3L GI-SR-RR/I-aGvHD 3L GI-SR-RR/I-aGvHD (~2,000 patients) • Ruxolitinib : ~70% MS in the US within 2
Slide 27: Realizing value through partnership
MaaT Pharma January 2025 27 Realizing value through partnership: Aligning innovation with unmet medical needs in hematology Unique Franchise Opportunity A very meaningful market opportunity Unique immunosuppressant-sparing, microbiome-based approach Well defined target population for both products,
Slide 28: End-to-End In-house cGMP Manufacturing Capabilities
End-to-End In-house cGMP Manufacturing Capabilities
Slide 29: Europe's Largest Specialized cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
→ cGMP All MET → Scalable MaaT Pharma November 2024 29 01 Europe’s Largest Leading microbiome therapies fully integrated Specialized cGMP manufacturing and development platform: streamlined product development, scaleup and GMP Manufacturing process. Facility for Microbiome Ecosystem Therapies 02 Opt
Slide 30: Newsflow & Funding Opportunities
Newsflow & Funding Opportunities
Slide 31: Several Major Near-Term Value Inflection Milestones
MaaT Pharma January 2025 Several Major Near-Term Value Inflection Milestones 31 2025 2026 2027 MaaT013 GvHD | Ares Ph3 28 days GI-ORR results Jan 25 MaaT013 GvHD | MA application EMA Mid 25 MaaT013 MaaT013 Hemato GvHD | Ares Ph3 OS results H2 25 GvHD | MA approval EMA H2 26 - MaaT013 MaaT013 Oncolog
Slide 32: Opportunities to fund the Company's development
MaaT Pharma January 2025 32 Opportunities to fund the Company's development Cash position of €27m as of September 30,2024 Current cash runway into Q2 2025 Exploring several opportunities to fund the Company's developments over the next coming years, including dilutive and non-dilutive options
Slide 33: Thank you
Thank you _ * 9@,S@ x rae nar,